8-K/A: Assertio Holdings Reports Q4 2023 Results, Provides 2024 Guidance Amidst Strategic Shift

Assertio Holdings reported its fourth quarter and full year 2023 results, highlighting the impact of the Rolvedon acquisition and generic competition for Indocin, while providing 2024 financial guidance.

Summary

• Assertio Holdings reported Q4 2023 total sales of $32.5 million, including $11 million from Rolvedon and $10.8 million from Indocin.
• Rolvedon sales increased sequentially since the acquisition in July 2023, and the company has addressed previous channel inventory issues.
• Indocin sales declined due to generic competition that began in August 2023.
• The company's gross margin was 70% in Q4, down from 88% in the prior year, due to inventory step-up amortization and changes in sales mix.
• SG&A expenses increased to $24 million, including $9.5 million from the Spectrum acquisition, with adjusted operating expenses at $21.8 million.
• Assertio reported a GAAP operating loss of $32.3 million, which included a $41 million impairment charge for intangible assets related to Indocin and a $17 million benefit from the change in fair value of the Indocin contingent liability.
• Adjusted EBITDA for Q4 was a positive $4.5 million.
• The company ended the year with $73.4 million in cash and $40 million in debt.
• For 2024, Assertio expects net product sales between $110 million and $125 million, with Rolvedon sales approaching $60 million and Indocin sales between $18 million and $25 million.
• Adjusted EBITDA for 2024 is projected to be between $20 million and $30 million, with adjusted operating expenses between $65 million and $70 million.
• The company anticipates ending 2024 with a cash balance between $90 million and $100 million.
• Assertio has reduced the size of its Rolvedon commercial organization to 32, including 16 field sales professionals, to focus on customer expansion and growth.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the company is showing growth in Rolvedon and is focused on cost efficiency, the negative impact of generic competition on Indocin and the resulting impairment charges and reduced margins temper the overall outlook. The company is also actively seeking acquisitions which could be positive or negative depending on the deal.

Positives

• Rolvedon sales are growing and are expected to be a significant growth driver for the company.
• The company has addressed the channel inventory issues that impacted Rolvedon sales.
• Assertio is focused on cost-efficient operations and cash generation.
• The company is actively seeking and evaluating potential business development transactions.
• The company is targeting to end 2024 with a cash balance between $90 million and $100 million.
• The company has a strong balance sheet with $73.4 million in cash and $40 million in debt.
• The company is operating cash flow positive.
• The company has a new board member with extensive business development experience.

Negatives

• Indocin sales are declining due to generic competition.
• The company's gross margin decreased from 88% to 70% due to inventory step-up amortization and changes in sales mix.
• The company reported a GAAP operating loss of $32.3 million in Q4 2023.
• The company recognized a $41 million impairment charge for intangible assets related to Indocin.
• The company expects continued unfavorability for Indocin sales due to generic competition throughout 2024.
• The company has assumed an additional generic entrant for Indocin in 2024.

Risks

• The company faces risks related to generic competition for Indocin, which is impacting sales and margins.
• The company's ability to grow sales of Rolvedon and achieve market acceptance is subject to risks.
• The company's ability to successfully develop and execute its sales, marketing and promotion strategies is subject to risks.
• The company's financial results could be impacted by the timing and impact of additional generic approvals.
• The company's ability to integrate new businesses successfully and realize cost savings and synergies is subject to risks.
• The company's ability to attract and retain executive leadership and key employees is subject to risks.
• The company's reliance on single-source suppliers for its products poses a supply chain risk.
• The company faces risks related to litigation and government investigations.
• The company's ability to maintain compliance with Nasdaq's minimum bid price requirement is a risk.
• The company's ability to obtain and maintain intellectual property protection for its products is a risk.

Future Outlook

Assertio expects net product sales in a range of $110 million to $125 million for 2024, with Rolvedon sales approaching $60 million and Indocin sales between $18 million and $25 million. The company anticipates adjusted EBITDA in a range of $20 million to $30 million and expects to remain cash positive in 2024.

Management Comments

• Heather Mason, Interim CEO, stated that Assertio's direction and financials have shifted as a result of the Rolvedon acquisition and generic competition for Indocin.
• Heather Mason emphasized the company's focus on cost-efficient operations and cash generation, with Rolvedon as the primary growth driver.
• Ajay Patel, CFO, highlighted that the 2022 fourth quarter was an all-time high for Indocin, which contributed to those overall results.
• Paul Schwichtenberg, Chief Commercial Officer, expressed excitement about Rolvedon's growth prospects and the company's commercial strategy.
• Paul Schwichtenberg mentioned that Rolvedon has acquired an estimated 30% share in current served markets and sees opportunity to continue to expand that market share.

Industry Context

The announcement reflects the challenges faced by pharmaceutical companies when generic competition enters the market, particularly for established products like Indocin. The company's strategic shift towards Rolvedon and its focus on cost efficiency are common responses to such market dynamics. The addition of a board member with extensive business development experience suggests a focus on growth through acquisitions, a common strategy in the pharmaceutical industry.

Comparison to Industry Standards

• Assertio's focus on acquiring and commercializing niche pharmaceutical products aligns with the strategies of companies like Horizon Therapeutics and Mallinckrodt, which also focus on acquiring and optimizing the sales of specialty drugs.
• The company's adjusted EBITDA margin guidance of approximately 18-24% (based on revenue guidance of $110-125 million and EBITDA guidance of $20-30 million) is within the range of profitability seen in similar specialty pharmaceutical companies, although the impact of generic competition on Indocin is a significant factor.
• The company's focus on reducing operating expenses and streamlining its commercial organization is a common practice in the pharmaceutical industry, especially when facing generic competition or integrating acquisitions. This is similar to actions taken by companies like Teva and Mylan when facing generic erosion of their branded products.
• The company's strategy of leveraging a non-personal digital promotion model is in line with the industry trend of using digital channels to reach healthcare professionals and patients, similar to strategies employed by companies like Veeva Systems and IQVIA.
• The company's focus on business development and acquisitions is a common strategy for growth in the pharmaceutical industry, with companies like AbbVie and Amgen actively pursuing acquisitions to expand their product portfolios.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the impact of generic competition on Indocin and the resulting impairment charges.
• Employees may be impacted by the reduction in the size of the Rolvedon commercial organization.
• Customers may benefit from the company's focus on Rolvedon and its value proposition.
• Creditors may be reassured by the company's focus on cash generation and debt management.

Next Steps

• The company will report its first quarter earnings results in May.
• The company will continue to seek and evaluate potential business development transactions.
• The company will provide updates on the Rolvedon same-day dosing trial as information becomes available.

Key Dates

Keywords

Rolvedon, Indocin, EBITDA, Generic Competition, Pharmaceuticals, Sales, Operating Expenses, Acquisition, Oncology, Financial Results